Ajanta Pharma launches pain relief tablets in US
New Delhi: Ajanta Pharma on Thursday announced launch of eletriptan hydrobromide tablets, used to treat headaches, in the US market.
"It is a bioequivalent generic version of Relpax tablets. Ajanta Pharma has launched the product in two strengths, 20 mg and 40 mg tablets," Ajanta Pharma said in a BSE filing.
Eletriptan hydrobromide tablets, the company said is a part its growing portfolio of products developed for the US market.
In total, Ajanta has 35 Abbreviated New Drug Applications (ANDAs) of which it has 19 final ANDA approvals, two tentative approvals, and 14 ANDAs under review with USFDA. So far it has launched 14 products in the US market.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd